Ambrosia Raises $100 Million Series B for Oral GLP-1 Obesity Pill, Entering Crowded Race
Biotech startup Ambrosia has closed a $100 million Series B round to advance its oral GLP-1 receptor agonist into early human testing, entering an increasingly competitive race to replace injectabl...
Biotech startup Ambrosia has closed a $100 million Series B round to advance its oral GLP-1 receptor agonist into early human testing, entering an increasingly competitive race to replace injectable weight-loss drugs with pills.
The Funding
- Amount: $100 million Series B
- Purpose: Early human testing of oral GLP-1
- Market: Anti-obesity therapeutics
The Oral GLP-1 Race
Ambrosia joins a crowded field of companies developing oral versions of GLP-1 drugs:
| Company | Approach | Stage |
|---|---|---|
| Novo Nordisk | Oral semaglutide (Rybelsus) | Approved (diabetes) |
| Ambrosia | Oral GLP-1 RA | Preclinical → Phase 1 |
| Kailera | Multiple GLP-1 candidates | Filed for IPO |
| Viking Therapeutics | Oral GLP-1/GIP | Clinical |
Why Oral Matters
The current generation of GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) requires weekly injections. An oral formulation would:
- Eliminate needle phobia — a major barrier to adoption
- Increase adherence — pills are easier to take consistently
- Expand market — reach patients who refuse injections
- Reduce costs — simpler manufacturing and distribution
Market Context
The global GLP-1 market is projected to exceed $150 billion by 2030. The shift from injectables to oral could unlock the next wave of growth.
← Previous: Hunterston B Nuclear Plant Transfers to UK Government Ownership as First AGR Enters DecommissioningNext: Perplexity Sued for Sharing User Conversations with Meta and Google Despite Incognito Mode →
0